

# CEAT shares dip 7% after Q3 net profit falls 46% to Rs 97 crore

ETMarkets.com • Last Updated: Jan 16, 2025, 12:52:00 PM IST

**Synopsis**  
CEAT shares: CEAT reported a 46.48% decline in consolidated net profit to Rs 97.03 crore for Q3 FY24, due to rising raw material costs. However, revenue grew to Rs 3,299.9 crore, driven by the replacement segment. Analysts maintain a 'Buy' recommendation with a target price of Rs 3,456, indicating a 13% upside.



Tyre maker CEAT shares dipped 7.11% to their day's low of Rs 2,840 on the BSE on Thursday, January 16, after the company reported a 46.48% decline in consolidated net profit to Rs 97.03 crore for the third quarter ended December 31, impacted by high raw material costs.


The company posted a consolidated net profit of Rs 181.28 crore in the same quarter last fiscal.

**YOU MAY LIKE**

**Soldes Blancheporte : Jusqu'à -80% sur toute la collection!**

Blancheporte.fr

Meanwhile, its consolidated revenue from operations stood at Rs 3,299.9 crore, compared to Rs 2,963.14 crore in the year-ago period.



Total expenses were higher at Rs 3,175.58 crore, compared to Rs 2,738.53 crore a year ago. The cost of materials consumed was Rs 2,116.52 crore, up from Rs 1,694.91 crore in the third quarter of the last fiscal, the company said.

"While rising raw material costs have impacted our margins, we progressively passed on part of the increase through price hikes in select categories during the quarter," CEAT Ltd MD & CEO Arnav Banerjee said.

### GrowFast with THE ECONOMIC TIMES

**ET Value**  
Stock Trading  
Maximise Returns by Investing in the Right Companies  
By: The Economic Times, Get Certified By India's Top Business News Brand  
[View Program](#)

**Market 101: Options Trading**  
Kickstart Your F&O Adventure  
By: Saketh R Founder- QuickAlpha, Full Time Options Trader  
[View Program](#)

He added that the strong year-on-year double-digit revenue growth was driven by the replacement segment.

On the outlook, he said, "Demand continues to remain stable, and our order book pipeline is robust across all segments. Raw material prices look flatfish in Q4, and we expect the growth momentum to continue."

Also Read: Q3 results today: RIL, Infosys among 37 companies to announce earnings on Thursday

**CEAT Shares Target Price**  
As per Trendlyne data, the average target price of the stock is Rs 3,456, indicating an upside potential of 13% from current market prices, the consensus recommendation from 17 analysts for the stock is a 'Buy'.

**CEAT Shares Performance**  
On Wednesday, CEAT shares closed at Rs 3,057, up 0.5% on the BSE, while the benchmark Sensex surged 0.29%. The stock has surged 12% over the past six months and 82% in the last two years. The company's market capitalization stands at Rs 12,367 crore.

*(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)*

**YOU MAY LIKE**

**Jusqu'à 5,99% avec ce**  
Nouvelle u Livret Bancaire!  
Rentabilité maximale de 5.99%, Ne s'applique qu'aux dépôts à terme, la durée maximale, la durée maximale.  
Actualisé en France [En savoir plus](#)

**Co-Founder of Google**  
Brain, Andrew Ng,  
Andrew Ng, computer scientist and technology entrepreneur  
Bilaliki! Andrew Ng's Reading List [En savoir plus](#)

**Comment se préparer à**  
l'ave nir de  
Une stratégie d'investissement tournée vers l'avenir et au-delà  
d'1000 Market Updates [Lisez la suite](#)

**Propriétaires: si vous êtes très endettés, essayez**  
Vous avez entre 45 et 75 ans et avez au moins 3 crédits en cours?  
Bon plan préparation [En savoir plus](#)

**Never Split the Difference: What a Former FBI Agent... Ce secret avant le petit**  
Thousands swear by the tips in the book.  
Never Split the Difference book...  
Bilaliki! Magar Lee [En savoir plus](#)

**Nutritionnistes stupéfaits**  
Une stratégie d'investissement tournée vers l'avenir et au-delà  
d'1000 Market Updates [Lisez la suite](#)

**Combien coûte une mutuelle qui rembourse**  
Melloussaux [En savoir plus](#)

**Retraités: votre mutuelle vous coute - de 67€/mois**  
Essayez ce comparateur en ligne  
Meilleure Mutuelle [En savoir plus](#)

**Voici ce que les experts recom mandent pour**  
ESB [En savoir plus](#)

(You can now subscribe to our **ETMarkets WhatsApp channel**)

READ MORE NEWS ON

[Ceat Shares](#) | [Ceat Share Price](#) | [Ceat Stock Price](#) | [Ceat Q3](#) | [Ceat Q3 Results](#) | [Ceat Ltd](#)

What's moving **Sensex** and **Nifty** Track **latest market news stock tips** **BL** **...** **more**

### Most Searched Stocks

IRFC Share Price	140.25
0359 PM   23 Jan 2025	-1.21(4.15%)
Suzlon Energy Share Price	55.12
0359 PM   23 Jan 2025	-1.23(2.4.03%)
IREDA Share Price	200.26
0359 AM   23 Jan 2025	-1.51(9.2.53%)
Tata Motors Share Price	742.75
0359 PM   23 Jan 2025	-1.18(0.2.37%)
YES Bank Share Price	18.35
0359 PM   23 Jan 2025	-1.01(5.0.82%)

[Load more...](#)

### Market Dashboard

NSE | BSE

TOP GAINERS	TOP LOSERS
<b>Colgate</b> 09:45 AM   23 Jan 2025 ₹ 822.80 (10.00%)	<b>9,051.00</b>
<b>Amber Enterprises</b> 09:45 AM   23 Jan 2025 ₹ 27.00 (8.39%)	<b>6,810.15</b>
<b>Persistent System</b> 09:45 AM   23 Jan 2025 ₹ 1471.31 (18.30%)	<b>6,154.45</b>
<b>Pidlite Ind</b> 09:45 AM   23 Jan 2025 ₹ 1209.81 (76.2%)	<b>2,964.55</b>

[View All Top Gainers](#)

### TRENDING IN MARKETS

Sensex Today | NSE | BSE Results

[Nifty Bank Q3 Results](#) | [Stocks in News](#)

### Latest from ET

- The self-help guru who shaped Donald Trump's path to success
- India-US working to arrange early Modi-Trump meet
- ₹509 cr gain helps HUL profit beat FMCG peers

Wishing You Confident Investing!  
Renew **ETPrime** at **₹4.1/day**  
Avail Offer

## NEXT STORY

# Navigating cardiovascular risk in people with type 2 diabetes mellitus

ET Spotlight • Last Updated: Jan 10, 2025, 11:23:00 AM IST

**Synopsis**  
The prevalence of Type 2 Diabetes Mellitus (T2DM) is rising globally, increasing cardiovascular disease (CVD) risk. Effective management strategies should include comprehensive control of blood glucose, blood pressure, and lipid levels, lifestyle changes, and the use of anti-diabetic medications to reduce CV events.



The continued global increase in the prevalence of type 2 diabetes mellitus (T2DM) poses a significant challenge to the health of individuals, societies, and nations. According to the 10th edition of the IDF Diabetes Atlas, 537 million adults (20-79 years) were living with diabetes in 2021, and this number is predicted to rise to 643 million by 2030 and 783 million by 2045<sup>1</sup>. Type 2 diabetes mellitus is increasingly being recognised as a significant risk factor for the occurrence of cardiovascular (CV) complications, including coronary artery disease, stroke, and peripheral artery disease. The interplay between T2DM and CV disease (CVD) is complex; understanding this risk and implementing strategies to mitigate it, is crucial for improving long-term outcomes in people with T2DM<sup>2</sup>.

Reducing CV risk in people with T2DM requires more than control of blood glucose values. It is essential to target blood pressure and serum lipid values as well. People with T2DM with impaired kidney function are at a very high risk of CVD, and as such, it is imperative to implement treatment strategies that safeguard kidney function.<sup>7</sup>

Effective management of excess weight in overweight or obese people with T2DM is essential to mitigate the risk of CVD associated with diabetes. Lifestyle modifications, behavioural strategies, pharmacological treatments, and, if necessary, surgical interventions to reduce weight in people with T2DM with obesity are crucial for reducing CV risk in this group of people.<sup>8</sup>

Moreover, all people with T2DM should be encouraged to quit smoking and adopt a healthy lifestyle, including a balanced diet and regular physical activity. Additional pharmacological treatments may be necessary to achieve optimal control of the associated cardiometabolic risk factors; also, one must consider using anti-diabetic medications with proven benefits in reducing CV events in people with T2DM with established atherosclerotic CVD or in those at high risk for CVD.<sup>1</sup>

Reducing CV risk in people with T2DM requires more than control of blood glucose values. It is essential to target blood pressure and serum lipid values as well. People with T2DM with impaired kidney function are at a very high risk of CVD, and as such, it is imperative to implement treatment strategies that safeguard kidney function.<sup>7</sup>

Effective management of excess weight in overweight or obese people with T2DM is essential to mitigate the risk of CVD associated with diabetes. Lifestyle modifications, behavioural strategies, pharmacological treatments, and, if necessary, surgical interventions to reduce weight in people with T2DM with obesity are crucial for reducing CV risk in this group of people.<sup>8</sup>

Moreover, all people with T2DM should be encouraged to quit smoking and adopt a healthy lifestyle, including a balanced diet and regular physical activity. Additional pharmacological treatments may be necessary to achieve optimal control of the associated cardiometabolic risk factors; also, one must consider using anti-diabetic medications with proven benefits in reducing CV events in people with T2DM with established atherosclerotic CVD or in those at high risk for CVD.<sup>1</sup>

Reducing CV risk in people with T2DM requires more than just control of blood glucose values. It is essential to target blood pressure and serum lipid values as well. People with T2DM with impaired kidney function are at a very high risk of CVD, and as such, it is imperative to implement treatment strategies that safeguard kidney function. Accessed on - [Link](#)

Rothberg AE et al. Obesity Management for the Treatment of Type 2 Diabetes. 2024 May 1; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK603314/> Accessed on - [Link](#)

**Conclusion**

- Diabetes mellitus significantly increases the risk of cardiovascular disease through various mechanisms.
- Comprehensive risk assessment, and individualised management strategies, are crucial for mitigating this risk.
- Appropriate lifestyle changes including diet control, regular exercise, and smoking cessation are essential in reducing CVD in people with T2DM.
- Effective blood glucose control and appropriate management of additional risk factors such as obesity, high blood pressure, and elevated lipid values can significantly improve cardiovascular outcomes in people with T2DM.
- Appropriate use of anti-diabetic medications with proven benefit in reducing CV events in people with T2DM with established CVD or in those at high risk for CVD shall further reduce the burden of CVD in people with T2DM.

- References**
- Ma CX, Ma XN, Guan CH, Li D, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. *Cardiovasc Diabetol.* 2022 May 14;21(1):74. doi: 10.1186/s12933-022-01516-6. PMID: 35568946; PMCID: PMC9107726. Accessed at [this link](#)
  - IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation, 2021. Available at: [Link](#)
  - Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. *Nat Rev Cardiol.* 2023 Oct;20(10):685-695. doi: 10.1038/s41569-023-00877-z. Epub 2023 May 16. PMID: 37193856. Accessed at [Link](#)
  - DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia.* 2010 Jul;53(7):1270-87. doi: 10.1007/s00125-010-1684-L. Epub 2010 Apr 2. PMID: 201661178; PMCID: PMC2877338. Accessed on [Link](#)
  - Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol.* 2018 May;34(5):575-584. doi: 10.1016/j.cjca.2017.12.005. Epub 2017 Dec 11. PMID: 29459239; PMCID: PMC5953551. Accessed on [Link](#)
  - Leiuu KH, Poppitt SD, Miles-Chan JL, Sequeira IR. Fatty Pancreas and Cardiometabolic Risk: Response of Ectopic Fat to Lifestyle and Surgical Interventions. *Nutrients.* 2022; 14(22):4873. [Link](#) Accessed on [Link](#)
  - Reduction in CV risk in people with T2DM requires more than just control of blood glucose values. It is essential to target blood pressure and serum lipid values as well. People with T2DM with impaired kidney function are at a very high risk of CVD, and as such, it is imperative to implement treatment strategies that safeguard kidney function. Accessed on - [Link](#)
  - Rothberg AE et al. Obesity Management for the Treatment of Type 2 Diabetes. 2024 May 1; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK603314/> Accessed on - [Link](#)

**Disclaimer:** This content is part of a disease awareness initiative by Novo Nordisk. The opinions and views are that of the Healthcare Professionals. The news and editorial staff of ET had no role in the creation of this article nor vouch for or endorse any of its content. While the content on this site provides general information about health and wellbeing, it is not intended as medical advice, nor is it a substitute for professional medical expertise or treatment. If you need help getting your health under control, we recommend speaking to your doctor.

**Artificial Intelligence(AI)**  
**Java Programming with ChatGPT:**  
Learn using Generative AI  
By: Neha Susha Sekhar, IT Specialist and Developer  
[View Program](#)

**Artificial Intelligence(AI)**  
**Basics of Generative AI: Unveiling Tomorrow's Innovations**  
By: Neha Susha Sekhar, IT Specialist and Developer  
[View Program](#)

(You can now subscribe to our **Economic Times WhatsApp channel**)

*(This article is generated and published by ET Spotlight team. You can get in touch with them on [etspotlight@timesintertv.in](mailto:etspotlight@timesintertv.in))*

READ MORE NEWS ON

[Navigating Cardiovascular](#) | [Type 2 Diabetes Mellitus](#) | [Cardiovascular Disease](#) | [CVD Risk Factors](#)

[Type 2 Diabetes Mellitus \(T2DM\)](#)

Catch all the **Business News Breaking News Budget 2024** Events and **LI** **...** **more**

**Lessons from the Grandmasters**

### Hot On Web

Salmonella outbreak in Canada | Airtel new voice and SMS plans | Minimalist News | HDFC Bank Share Price | [MORE](#)

How you Missed It  
Share | IREDA Q3 Results | Reliance Power Preferential Issue | Manba Finance IPO | [MORE](#)

Shudon Companies  
Shudon share price | IREDA share price | Tata Motors share price | Yes bank share price | [MORE](#)

Calculators  
Loan Calculator | Income Tax Calculator | Age Calculator | SIP Calculator | Time Calculator | [MORE](#)

Calculations  
Repo Rate | Mpsko Builders Private Limited | Currency Symbol | [MORE](#)

Listing  
Stock Market Crash | Sgs Nifty | Earthquake Today | [MORE](#)

How  
Axis Bank | Icici Bank | Axis Bank | How Rajendra Badwe Is Making... | [MORE](#)

Companies  
L1 | Mabigo Labs Private Limited | Pyramid Sainira Theatre Ltd Sh... | [MORE](#)

Commodities  
Aluminium Rate | Silver Rate | Copper Rate | Gold Rate | [MORE](#)

Articles  
India is Streamlin... | Adani Group Stocks Will Average... | After Adani Stocks Hit New... | [MORE](#)

Hot Pages  
Finance | [MORE](#)

Hot Links  
How to... | Terms of Use & Grievance Redressal | Economic Times ePaper | GrowFast | Privacy policy | [MORE](#)

News  
Expect demand moderation to continue... | Scarlett Johansson shocked when husband... | Netflix reports record-breaking Q4 earnings... | Waaree Energies begins commercial production... | [MORE](#)

6 Things you should... | Can Bitcoin reach... | India's Trump shocker - Following his father's... | Musk's job bonus after... | James Dimon praises former legendary Equ... | Prince Harry revealed

### We Care About Your Privacy

We and our **167** partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide", whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom-left of the webpage [or the floating icon on the bottom-right of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy [Cookie Policy](#)

We and our partners process data to provide:

- Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

I Accept

Reject All

Show Purposes

